Form 4: TuHURA Biosciences Director James Manuso Acquires Options in Annual Grant

Director James Manuso acquired options for 59,590 shares of TuHURA Biosciences common stock as part of the company's Non-Employee Director Compensation Program.

Summary

• James Manuso, a director of TuHURA Biosciences, acquired options to purchase 59,590 shares of common stock on January 2, 2025.
• The options were granted as part of the company's Non-Employee Director Compensation Program.
• The exercise price of the options is $4.11.
• The options expire on January 2, 2035.
• One-third of the options become exercisable on each of the first, second, and third anniversaries of the grant date.

Sentiment

Score: 6

Explanation: The document is a routine filing related to director compensation, indicating standard corporate governance practices. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Positives

• The option grant aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Option grants to directors are a common practice in publicly traded companies to incentivize and align their interests with those of shareholders.

Comparison to Industry Standards

• Director compensation packages, including option grants, vary significantly across the biotechnology industry depending on company size, stage of development, and board composition.
• Comparing the size and terms of this option grant to those of directors at similar-stage biotech companies (e.g., those with comparable market capitalization and clinical development pipelines) would provide a benchmark for assessing its competitiveness and appropriateness.

Stakeholder Impact

• Shareholders may view the option grant as a positive incentive for the director to act in their best interests.
• The option grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates